eXoZymes, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from eXoZymes, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-18.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 57% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-19.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 54% of Healthcare companies in United States.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
eXoZymes, Inc. made a loss over the last year. eXoZymes, Inc. owes $0.54 for every $1 it owns. eXoZymes, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LosseXoZymes, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
9.93The share price is 9.93 times eXoZymes, Inc.'s book value per share, higher than 86% of Healthcare companies in United States.
Market cap
$36 MThe total market value of all of eXoZymes, Inc.'s shares at today's price (share price × number of shares), smaller than 78% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$4 MWhat eXoZymes, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.39Net worth divided by the number of shares. The share price of $3.90 is 9.9 times this, which is the P/B above.
Return on equity (ROE)
-187.2%eXoZymes, Inc. lost 187.2% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
Owes vs Owns
0.54×eXoZymes, Inc. owes $0.54 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Dividend yield
NoneeXoZymes, Inc. does not currently pay a dividend.
Profit growth
LosseXoZymes, Inc. made a loss in each of the last two years.
Cash vs debt
Net casheXoZymes, Inc. held $2 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For eXoZymes, Inc.: $36 M ÷ $4 M (30 Jun 2026) = 9.9.
What is eXoZymes, Inc.'s return on equity?
eXoZymes, Inc. lost 187.2% of its shareholders' money over the last year, lower than 83% of Healthcare companies in United States.
How much does eXoZymes, Inc. owe compared with what it owns?
eXoZymes, Inc. owes $0.54 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Does eXoZymes, Inc. pay a dividend?
No. eXoZymes, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.